- Nepali becomes youngest to climb world's 8,000m peaks
- Climate change made deadly Hurricane Helene more intense: study
- A US climate scientist sees hurricane Helene's devastation firsthand
- Padres edge Dodgers, Mets on the brink
- Can carbon credits help close coal plants?
- With EU funding, Tunisian farmer revives parched village
- Sega ninja game 'Shinobi' gets movie treatment
- Boeing suspends negotiations with striking workers
- 7-Eleven owner's shares spike on report of new buyout offer
- Your 'local everything': what 7-Eleven buyout battle means for Japan
- Three million UK children living below poverty line: study
- China's Jia brings film spanning love, change over decades to Busan
- Paying out disaster relief before climate catastrophe strikes
- Chinese shares drop on stimulus upset, Asia tracks Wall St higher
- SE Asian summit seeks progress on Myanmar civil war
- How climate funds helped Peru's women beekeepers stay afloat
- Nobel Peace Prize to be awarded as wars rage
- Pacific island nations swamped by global drug trade
- AI-aided research, new materials eyed for Nobel Chemistry Prize
- Mozambique elects new president in tense vote
- The US economy is solid: Why are voters gloomy?
- Balkan summit to rally support for struggling Ukraine
- New stadium gives Real Madrid a headache
- Alonso, Manaea shine as 'Miracle Mets' blitz Phillies
- Harris, Trump trade blows in US election media blitz
- Harry's Bar in Paris drinks to US straw-poll centenary
- Osama bin Laden's son Omar banned from returning to France
- Afghan man arrested for plotting US election day attack
- Brazil lifts ban on Musk's X, ending standoff over disinformation
- Harris holds slight edge nationally over Trump: poll
- Chelsea edge Real Madrid in Women's Champions League, Lyon win
- Japan PM to dissolve parliament for 'honeymoon' snap election
- 'Diego Lives': Immersive Maradona exhibit hits Barcelona
- Brazil Supreme Court lifts ban on Musk's X
- Scientists sound AI alarm after winning physics Nobel
- Six-year-old girl among missing after Brazil landslide
- Nobel-winning physicist 'unnerved' by AI technology he helped create
- Mexico president rules out new 'war on drugs'
- Israeli defense minister postpones trip to Washington: Pentagon
- Europe skipper Donald in talks with Garcia over Ryder return
- Kenya MPs vote to impeach deputy president in historic move
- Former US coach Berhalter named Chicago Fire head coach
- New York Jets fire head coach Saleh: team
- Australia crush New Zealand in Women's T20 World Cup
- US states accuse TikTok of harming young users
- 'Evacuate now, now, now': Florida braces for next hurricane
- US Supreme Court skeptical of challenge to 'ghost guns' regulation
- Sparks fly as Orban berates EU 'elites' in parliament trip
- US finalizes rule to remove lead pipes within a decade
- Solanke hungry for second England cap after seven-year wait
Pfizer Q1 revenues jump 77% to $25.7 bn on Covid-19 vaccine
Pfizer reported another quarter of huge revenues growth because of its Covid-19 vaccine on Tuesday, but lowered the company's full-year profit forecast due in part to shifts in foreign exchange.
The major American drugmaker reported revenues of $25.7 billion for the first quarter, up 77 percent from the year-ago period, with the Covid vaccine taking in $13.2 billion.
Net income jumped 61 percent to $7.9 billion.
Pfizer confirmed its full-year revenues forecast, in which about just over half of total sales stem from the Covid-19 innoculation and from Paxlovid, the company's therapeutic to treat the coronavirus.
Pfizer, which has shipped some 3.4 billion doses of vaccine to 179 countries, has won regulatory approval for its shot in most age groups, but continues to study its use in children younger than five.
The company is also exploring "potential next-generation vaccines, including variant vaccines" for the fall season, Chief Executive Albert Bourla said in prepared remarks.
In the first quarter, Paxlovid took in $1.5 billion in global sales. But Pfizer expects 2022 sales of the medicine of $22 billion as it ramps up production and distribution.
The World Health Organization last month "strongly recommended" the antiviral pill Paxlovid for patients with milder forms of the disease who were still at a high risk of hospitalization.
But WHO said it was "extremely concerned" that low- and middle-income countries would be "pushed to the end of the queue" amid tight global supplies.
Pfizer now sees full-year adjusted profits of $6.25 to $6.45 a share, down 10 cents from the previous range.
The company attributed the lowered forecast to an accounting change in research and development expenses and to changes in the foreign exchange market that have seen the dollar rise compared with other major currencies.
Shares of Pfizer dipped 1.2 percent to $47.77 in pre-market trading.
M.Thompson--AMWN